Enhancement of human immunodeficiency virus type 1-DNA vaccine potency through incorporation of T-helper 1 molecular adjuvants

Immunological Reviews
Sandra A Calarota, David B Weiner

Abstract

It is clear that the development of a safe and effective vaccine for human immunodeficiency virus type 1 (HIV-1) remains a crucial goal for controlling the acquired immunodeficiency syndrome epidemic. At present, it is not clear what arm of the immune response correlates with protection from HIV-1 infection or disease. Therefore, a strong cellular and humoral immune response will likely be needed to control this infection. Among different vaccine alternatives, DNA vaccines appeared more than a decade ago, demonstrating important qualities of inducing both humoral and cellular immune responses in animal models. However, after several years and various clinical studies in humans, supporting the safety of the HIV-DNA vaccine strategies, it has become clear that their potency should be improved. One way to modulate and enhance the immune responses induced by a DNA vaccine is by including genetic adjuvants such as cytokines, chemokines, or T-cell costimulatory molecules as part of the vaccine itself. Particularly, vaccine immunogenicity can be modulated by factors that attract professional antigen-presenting cells, provide additional costimulation, or enhance the uptake of plasmid DNA. This review focuses on developments in the coad...Continue Reading

References

Sep 1, 1992·The Journal of Experimental Medicine·R AlamJ A Grant
Jun 1, 1994·Immunology Today·R Hohlfeld, A G Engel
Apr 26, 1994·Proceedings of the National Academy of Sciences of the United States of America·M W CarrT A Springer
May 1, 1993·Proceedings of the National Academy of Sciences of the United States of America·B WangD B Weiner
May 20, 1996·AIDS Research and Human Retroviruses·M A PeralesJ Lieberman
Sep 17, 1996·Proceedings of the National Academy of Sciences of the United States of America·E L JacobsonK A Smith
Oct 31, 1996·The New England Journal of Medicine·J A KovacsH C Lane
Aug 19, 1997·Proceedings of the National Academy of Sciences of the United States of America·N L LetvinJ W Shiver
Aug 26, 1998·Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research·J J KimD B Weiner
Sep 17, 1998·The Journal of Clinical Investigation·J J KimD B Weiner
Jan 13, 1999·Clinical Immunology : the Official Journal of the Clinical Immunology Society·J D BoyerD B Weiner
Mar 17, 1999·The Journal of Clinical Investigation·J J KimD B Weiner
Jul 22, 1999·Clinical Immunology : the Official Journal of the Clinical Immunology Society·K Q XinK Okuda
Oct 3, 1999·Vaccine·J D BoyerD B Weiner
Mar 8, 2000·The Journal of Immunology : Official Journal of the American Association of Immunologists·K KusakabeK Okuda
Apr 12, 2000·Proceedings of the National Academy of Sciences of the United States of America·D H BarouchN L Letvin
Jun 7, 2000·Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research·J J KimD B Weiner

❮ Previous
Next ❯

Citations

Oct 13, 2006·Springer Seminars in Immunopathology·Lindvi GudmundsdotterBritta Wahren
Oct 13, 2006·Springer Seminars in Immunopathology·David A Hokey, David B Weiner
Mar 9, 2006·Current HIV/AIDS Reports·Isaac R Rodriguez-ChavezM Patricia D'Souza
May 7, 2009·Molecular Therapy : the Journal of the American Society of Gene Therapy·Dorian McIlroyBruno Pitard
Jan 26, 2008·Nature Reviews. Cancer·Jason RiceFreda K Stevenson
Oct 13, 2006·Human Gene Therapy·Margaret A LiuGunilla B Karlsson Hedestam
Jan 27, 2011·Drug Design, Development and Therapy·Lena J Gamble, Qiana L Matthews
Jan 1, 2009·Experimental & Molecular Medicine·Chae Young KimByung Gee Kim
Mar 29, 2014·Current Opinion in HIV and AIDS·M Anthony Moody
Dec 23, 2006·Expert Review of Vaccines·Wolfgang Jechlinger
Dec 14, 2011·Expert Review of Vaccines·Abbas MuhammadPavol Kudela
Oct 6, 2007·Expert Opinion on Biological Therapy·Julianna LisziewiczFranco Lori
Jun 30, 2012·Cytokine & Growth Factor Reviews·Morgan A ReuterMichael R Betts
Nov 16, 2010·Cytokine & Growth Factor Reviews·Antonio Di SabatinoGino R Corazza
May 27, 2008·The Veterinary Clinics of North America. Small Animal Practice·Stephen P Dunham, Elizabeth Graham
May 9, 2008·Vaccine·Sandra A CalarotaJulianna Lisziewicz
Feb 26, 2008·Veterinary Immunology and Immunopathology·Elizabeth W UhlJanet K Yamamoto
Apr 7, 2010·Journal of Biomedicine & Biotechnology·Daniela FiorettiMonica Rinaldi
Jun 10, 2006·Hematology/oncology Clinics of North America·Rodica StanAdam D Cohen
Apr 10, 2009·International Journal of Cancer. Journal International Du Cancer·Peter OhlschlägerAndreas M Kaufmann
Mar 24, 2010·International Journal of Cancer. Journal International Du Cancer·Peter OhlschlägerMarcus Groettrup
May 27, 2006·Vaccine·Wolfgang W LeitnerNicholas P Restifo
Sep 3, 2005·Vaccine·David F GardinerDavid D Ho
Nov 3, 2004·The Journal of Clinical Investigation·Michele A Kutzler, David B Weiner
Aug 25, 2012·Acta Biochimica Et Biophysica Sinica·Yi ZhangHong Cai
Mar 30, 2011·Brazilian Journal of Medical and Biological Research = Revista Brasileira De Pesquisas Médicas E Biológicas·M O Diniz, L C S Ferreira
Jun 8, 2018·Expert Opinion on Biological Therapy·Lorenzo PillaCristina Maccalli
Aug 26, 2006·Journal of Leukocyte Biology·Richard S Kornbluth, Geoffrey W Stone
Mar 13, 2013·Current Opinion in HIV and AIDS·Giuseppe Pantaleo, Yves Lévy
Aug 7, 2007·The Journal of Immunology : Official Journal of the American Association of Immunologists·Erika L Pearce, Hao Shen

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.